EF Hutton Maintains Buy on Annovis Bio, Maintains $21 Price Target

Benzinga · 10/15 16:38
EF Hutton analyst Jason Kolbert maintains Annovis Bio (NYSE:ANVS) with a Buy and maintains $21 price target.